Journal
BIOTECHNOLOGY AND BIOENGINEERING
Volume 104, Issue 2, Pages 371-380Publisher
WILEY
DOI: 10.1002/bit.22416
Keywords
viral clearance; virus chromatography; anion exchange chromatograogt (AEX); Q sepharose fast flow (QSFF); chromatofocusing
Categories
Funding
- Div Of Chem, Bioeng, Env, & Transp Sys
- Directorate For Engineering [0854151] Funding Source: National Science Foundation
Ask authors/readers for more resources
During production of therapeutic monoclonal antibodies (mAbs) in mammalian cell culture, it is important to ensure that viral impurities and potential viral contaminants will be removed during downstream purification. Anion exchange chromatography provides a high degree of virus removal from mAb feedstocks, but the mechanism by which this is achieved has not been characterized. In this work, we have investigated the binding of three viruses to Q sepharose fast flow (QSFF) resin to determine the degree to which electrostatic interactions are responsible for viral clearane by this process. We first used a chromatofocusing technique to determine the isoelectric points of the viruses and established that they are negatively charged under standard QSFF conditions. We then determined that virus removal by this chromatography resin is strongly disrupted by the presence of high salt concentrations or by the absence of the positively charged Q ligand, indicating that binding of the virus to the resin is primarily due to electrostatic forces, and that any non-electrostatic interactions which may be present are not sufficient to provide virus removal. Finally, we determined the binding profile of a virus in a QSFF column after a viral clearance process. These data indicate that viruus particles generally behave similarly to proteins, but they also illustrate the high degree of performance necessary to achieve several logs of virus reduction. Overall, this mechanistic understanding of an important viral clearance process provides the foundation for the development of science-based process validation strategies to ensure viral safety of biotechnology products. Biotechnol. Bioeng. 2009;104: 371-380. (C) 2009 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available